Introduction:

Artificial Pancreas Device Systems Market was valued at US$ 278.1 Million in 2024 and is projected to grow at a CAGR of 17.40% to reach US$ 1361.5 Million by 2034.

The pancreas is an organ in the body that produces and secretes digestive fluids. The pancreases, which create digestive enzymes including trypsin and chymotrypsin, are bordered by the small intestine, spleen, stomach, liver, and gall bladder. An artificial pancreas system monitors blood glucose levels and acts as a substitute for the pancreas' endocrine function. In order to lower high blood glucose levels, it automatically modifies insulin supply in addition to monitoring the body's glucose level.

Growing government initiative in clinical research, increasing need for remote monitoring applications and home care setup devices are the key factors in the growth of the market. Growing demand for automated systems in glycemic control and rising research & development activities has contributed in the growth of Artificial Pancreas Device Systems Market.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Rising Prevalence of Diabetes

The prevalence of diabetes is rising globally, which is raising demand for advanced diabetes treatment solutions. Artificial pancreas device systems mimic the function of a healthy pancreas by automatically regulating blood glucose levels, making it a possible treatment for diabetes. Urbanization, ageing population, decreasing levels of physical activity, increasing overweight and obesity prevalence are the key contributors that drives the growth of Artificial Pancreas Device Systems Market.

For instance, in 2021, according to Centers for Disease Control and Prevention (CDC), in U.S the average country level prevalence of diagnosed diabetes increased from 6.3% in 2004 to 8.4% in 2019. Total diagnosed diabetic patients are 37.3 million which is about 11.3% of the U.S population, about 28.7 million adults is diagnosed with diabetes and about 8.5 million adults are still not yet diagnosed.

Technological Advancements in Artificial Pancreas Device Systems

The safety, effectiveness, and simplicity of managing diabetes have all increased due to advancements in artificial pancreas device system technology. Novel approaches in T1DM treatment have been formed by technical advancements in insulin pumps and continuous glucose monitoring devices which has provided boost in the development of artificial pancreas systems. Growing demand for glycemic control offered by artificial pancreas device systems over conventional treatments has given the rapid boost in the target market growth.

For instance, in January 2020, Control-IQ which is manufactured by Tandem Diabetes Care has been approved by the U.S. Food and Drug Administration (FDA). It automatically tracks blood glucose levels with a continuous glucose monitor (Dexcom G6 CGM) and delivers the hormone insulin as needed. The pump is programmed with an algorithm developed at university of Virginia (UVA) that uses glucose monitoring information to adjust the recipient’s insulin dose automatically.

Restrains:

Despite the impressive clinical outcomes arising from artificial pancreas use, calibration difficulties, equipment failure, disturbed sleep due to alarms, and issues with wearing and managing several devices are the factors that restrain the target market growth. Artificial pancreas device systems are usually costly especially if not covered by insurance, insurance coverage or qualifications for coverage are usually an issue which limits the growth of Artificial Pancreas Device Systems Market.

Artificial Pancreas Device Systems Market is segmented based on Type and Region.

Type Insight

On the basis of Type, Artificial Pancreas Device Systems Market is segmented into Control to Range, Control to Target, and Threshold-Suspended Device Systems. Threshold-suspended device systems segment is expected to dominate the target market growth as this device automatically takes action when the patient is unable to respond to threshold suspend alarm and stops insulin delivery when the value of sensor glucose reaches a low threshold.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On the basis of region, the Artificial Pancreas Device Systems Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to factors such as increasing prevalence of obesity & diabetes. The presence of efficient reimbursement policies, growing awareness about advanced technologies in diabetes management and the presence of key companies with new product launch are anticipated to increase demand for Artificial Pancreas Device Systems in the region.

Report Scope:

Attribute	Details
Market Size 2024	US$ 278.1 Million
Projected Market Size 2034	US$ 1361.5 Million
CAGR Growth Rate	17.4%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Type - Control to Range, Control to Target, and Threshold-Suspended Device Systems
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Artificial Pancreas Device Systems Market report based on Type and region:

Artificial Pancreas Device Systems Market, By Type:

• Control to Range
• Control to Target
• Threshold-Suspended Device Systems

Artificial Pancreas Device Systems Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating the Artificial Pancreas Device Systems Market includes, Defymed SAS, TypeZero Technologies, Inc., Insulet Corporation, Bigfoot Biomedical, Inc., Medtronic Plc, Dexcom, Inc., Admetsys Corp., Beta Bionics, Inc., Cellnovo Group SA, and Tandem Diabetes Care, Inc.

• Defymed SAS*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• TypeZero Technologies, Inc.
• Insulet Corporation
• Bigfoot Biomedical, Inc.
• Medtronic Plc, Dexcom, Inc.
• Admetsys Corp.
• Beta Bionics, Inc.
• Cellnovo Group SA
• Tandem Diabetes Care, Inc.

“*” marked represents similar segmentation in other categories in the respective section

Recent Development:

• In January 2020, the US Food and Drug Administration (FDA) approved an artificial pancreas system for type 1 diabetes patients known as “Control-IQ”, which is manufactured by Tandem Diabetes Care. It is based on technology from the University of Virginia Center for Diabetes Technology, it tracks blood glucose levels with a continuous glucose monitor and automatically delivers the hormone insulin when needed. The device relieves users of the need for several daily fingerstick blood sugar checks and many daily insulin injections.
• In June 2017, Medtronic plc., launched ‘MiniMed (TM) 670G’ system the world's first Hybrid Closed Loop system for people with type 1 diabetes and SmartGuard (TM) HCL technology and Guardian (TM) Sensor 3 which was approved by the Food and Drug Administration (FDA). it is the only insulin pump that enables personalized and automated delivery of basal insulin and the background insulin required to keep blood sugar levels steady all day and all night.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Preview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Type
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Artificial Pancreas Device System Market, By Type
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Control to Range
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2022 – 2032
   • Control to Target
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2022 – 2032
   • Threshold-Suspended Device Systems
     • Overview
     • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2022 – 2032
6. Artificial Pancreas Device System Market, By Region, 2022 – 2032, (US$ Mn)
   • Overview
     • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Mn), By Type, 2022 – 2032
     • Market Size and Forecast (US$ Mn), By Country, 2022 – 2032
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Mn), By Type, 2022 – 2032
     • Market Size and Forecast (US$ Mn), By Country, 2022 – 2032
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Mn), By Type, 2022 – 2032
     • Market Size and Forecast (US$ Mn), By Country, 2022 – 2032
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific

• • Latin America
    • Market Size and Forecast (US$ Mn), By Type, 2022 – 2032
    • Market Size and Forecast (US$ Mn), By Country, 2022 – 2032
• • • • Brazil
      • Mexico
      • Rest of Latin America
  • Middle East & Africa
    • Market Size and Forecast (US$ Mn), By Type, 2022 – 2032
    • Market Size and Forecast (US$ Mn), By Country, 2022 – 2032

1. • • • GCC
       • Israel
       • South Africa
       • Rest of Middle East
2. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
3. Company Profiles

 

• Defymed SAS
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• TypeZero Technologies, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Insulet Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bigfoot Biomedical, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Medtronic Plc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Dexcom, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Admetsys Corp.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Beta Bionics, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Cellnovo Group SA
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Tandem Diabetes Care, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact